A 2021–2026 systematic review of phase 2 and 3 trials found that next-generation obesity medicines deliver benefits far beyond the scale: GLP-1 agents produced about 10%–15% weight loss, tirzepatide, CagriSema, and amycretin exceeded 20%, and retatrutide exceeded 25%, while also improving complications across cardiometabolic and organ-specific disease. The review argues for a treat-to-target, complication-centric approach to obesity care — exactly the kind of longitudinal, patient-centered management NPs and PAs are built to lead.

Why It Matters To Your Practice

• Obesity is a chronic, relapsing disease, not a side issue — and frontline clinicians are often the ones patients trust most to start treatment, adjust therapy, and sustain momentum.

• This evidence supports moving beyond “weight loss only” goals toward phenotype-guided care focused on complications, function, and metabolic health.

• That plays directly to NP and PA strengths: continuity, coaching, medication management, and seeing the whole patient rather than a single number.

Clinical Benefits

• Newer therapies affect multiple pathways including GLP-1, GIP, amylin, and glucagon, helping regulate appetite, energy balance, and metabolic homeostasis.

• Benefits extend beyond weight reduction, with improvements in glycemia, diabetes prevention, cardiovascular outcomes, heart failure symptoms, obstructive sleep apnea, metabolic dysfunction-associated steatohepatitis, chronic kidney disease progression, and osteoarthritis-related pain.

• For patients with obesity and Diabetes mellitus (DM) or prediabetes, these agents can support more meaningful risk reduction than a weight-centric conversation alone.

Managing Risks

• Successful use requires individualized therapy selection, monitoring for tolerability and long-term safety, and setting realistic expectations about chronic treatment.

• Access remains a major barrier, so prior authorization, affordability, and equitable delivery are part of the clinical job — and often where skilled NPs and PAs make the difference between a prescription written and a treatment actually started.

• Patients will need ongoing follow-up for adherence, response, adverse effects, and adjustment of broader care plans as complications improve or evolve.

The Bottom Line

• The science is clear: obesity pharmacotherapy is becoming complication-centric, target-driven, and far more effective.

• The opportunity is just as clear: NPs and PAs are not supporting players here — you are the clinicians best positioned to operationalize this care at scale, translate evidence into action, and lead the next era of obesity treatment.